Molecular Partners Ag ADR (MOLN) Stock Price, Quote & News

Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting t...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 44 755 77 00

Fax: 41 44 755 77 07

Website: www.molecularpartners.com

Address:

Wagistrasse 14, Schlieren, Switzerland

OfficialStocktwitsUser Feb. 22 at 10:08 PM

$MOLN RSI: 75.00, MACD: 0.1742 Vol: 0.31, MA20: 4.51, MA50: 4.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

WhisperScout Feb. 18 at 8:02 AM

$MOLN Molecular or unknown micro-cap with minimal public information and likely speculative.

0 · Reply

briefingcom Feb. 2 at 12:44 PM

$MOLN: Molecular Partners AG presents first imaging and dosimetry data for DLL3-targeting radiotherapy MP0712 at TWC 2026 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260202051144MOLN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

BillionerOfKing Jan. 30 at 12:55 PM

$MOLN Current Stock Price: $4.15

0 · Reply

DARKP00L Jan. 27 at 1:17 PM

$MOLN

0 · Reply

DARKP00L Jan. 27 at 11:18 AM

$MOLN 06:16 on Jan. 27 2026 HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13 #tradeideas

0 · Reply

Milos89 Jan. 25 at 2:13 AM

$MOLN

0 · Reply

briefingcom Jan. 12 at 1:11 PM

$MOLN: Molecular Partners (+3.8%) highlights clinical development progress and anticipated milestones at 44th Annual J.P. Morgan Healthcare Conference

0 · Reply

FiscalCycleNavigator Dec. 27 at 8:26 AM

$MOLN Momentum persists only for businesses proving consistency quarter to quarter. Forecast reliability has room to improve materially. Credible progress tends to compress risk premiums. Ultimately, disciplined delivery will shape the outcome.

0 · Reply

SuperGreenToday Dec. 22 at 5:20 PM

$MOLN

0 · Reply

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 - Slideshow

2026-02-02T21:10:28.000Z - 21 days ago

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript

2026-02-02T18:00:11.000Z - 21 days ago

Molecular Partners AG conference call and Webcast Transcript

Mon, 02 Feb 2026 01:00:00 -0500 - 22 days ago

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

2026-01-19T23:04:25.000Z - 5 weeks ago

Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-15T22:16:01.000Z - 5 weeks ago

Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Thu, 18 Dec 2025 01:00:00 -0500 - 2 months ago

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

Sun, 07 Dec 2025 07:00:00 -0500 - 2 months ago

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

2025-11-13T00:41:40.000Z - 3 months ago

Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript

Wed, 12 Nov 2025 01:00:00 -0500 - 3 months ago

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

Mon, 03 Nov 2025 01:00:00 -0500 - 4 months ago

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Mon, 03 Nov 2025 01:00:00 -0500 - 4 months ago

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

Thu, 30 Oct 2025 16:00:00 -0400 - 4 months ago

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

2025-09-03T20:00:36.000Z - 6 months ago

Looking Into Molecular Partners's Recent Short Interest

2025-09-03T16:34:43.000Z - 6 months ago

Molecular Partners (MOLN) Stock Rating Maintained by JP Morgan | MOLN Stock News

2025-08-26T12:08:12.000Z - 6 months ago

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Tue, 26 Aug 2025 08:08:12 -0400 - 6 months ago

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Mon, 25 Aug 2025 16:00:00 -0400 - 6 months ago

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Sun, 22 Jun 2025 16:00:00 -0400 - 8 months ago

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

2025-06-10T08:03:03.000Z - 9 months ago

Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028

Tue, 10 Jun 2025 01:58:17 -0400 - 9 months ago

Molecular Partners to cut workforce by a quarter

Tue, 10 Jun 2025 01:00:00 -0400 - 9 months ago

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

Mon, 19 May 2025 01:00:00 -0400 - 10 months ago

Molecular Partners to Present at Upcoming Investor Conferences

2025-05-16T09:43:10.000Z - 10 months ago

Molecular Partners reports Q1 results

2025-05-13T05:18:58.000Z - 10 months ago

Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade)

Fri, 25 Apr 2025 16:00:00 -0400 - 10 months ago

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Wed, 16 Apr 2025 12:00:00 -0400 - 11 months ago

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Tue, 25 Mar 2025 16:00:00 -0400 - 11 months ago

Molecular Partners to hold three poster presentations at AACR 2025

Tue, 25 Mar 2025 12:00:00 -0400 - 1 year ago

Molecular Partners Publishes Invitation to Annual General Meeting 2025

Fri, 07 Mar 2025 11:59:35 -0500 - 1 year ago

Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript

2025-03-06T21:49:50.000Z - 1 year ago

Molecular Partners GAAP EPS of -CHF1.59, revenue of CHF5.0M

Thu, 06 Mar 2025 16:00:00 -0500 - 1 year ago

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Fri, 28 Feb 2025 01:00:00 -0500 - 1 year ago

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Wed, 15 Jan 2025 15:04:40 -0500 - 1 year ago

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

2025-01-13T09:23:32.000Z - 1 year ago

Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer

Sun, 12 Jan 2025 13:00:00 -0500 - 1 year ago

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Sun, 12 Jan 2025 13:00:00 -0500 - 1 year ago

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Tue, 17 Dec 2024 16:00:00 -0500 - 1 year ago

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Sun, 08 Dec 2024 12:00:00 -0500 - 1 year ago

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Thu, 07 Nov 2024 16:00:00 -0500 - 1 year ago

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Thu, 31 Oct 2024 16:00:00 -0400 - 1 year ago

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

2024-10-25T05:45:41.000Z - 1 year ago

Molecular Partners prices $20M offering

Fri, 25 Oct 2024 01:00:00 -0400 - 1 year ago

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

2024-10-22T14:19:58.000Z - 1 year ago

Molecular Partners stock climbs 6% on expanded radiopharmaceuticals deal

Tue, 22 Oct 2024 01:00:00 -0400 - 1 year ago

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Tue, 22 Oct 2024 01:00:00 -0400 - 1 year ago

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Fri, 04 Oct 2024 01:00:00 -0400 - 1 year ago

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Fri, 27 Sep 2024 01:00:00 -0400 - 1 year ago

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

2024-08-26T20:38:10.000Z - 1 year ago

Molecular Partners reports 1H results

Mon, 26 Aug 2024 16:00:00 -0400 - 1 year ago

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Aug 7, 2024, 5:37 AM EDT - 1 year ago

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Jun 17, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Jun 14, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Jun 11, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

May 16, 2024, 4:00 PM EDT - 1 year ago

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

Apr 29, 2024, 11:00 AM EDT - 1 year ago

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Apr 19, 2024, 11:12 AM EDT - 2 years ago

Life Science Cares Launches in Switzerland

Apr 17, 2024, 11:12 AM EDT - 2 years ago

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Mar 26, 2024, 9:26 AM EDT - 2 years ago

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Mar 15, 2024, 11:20 AM EDT - 2 years ago

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 4:00 PM EDT - 2 years ago

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Mar 1, 2024, 4:00 PM EST - 2 years ago

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Jan 7, 2024, 4:00 PM EST - 2 years ago

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

OfficialStocktwitsUser Feb. 22 at 10:08 PM

0 · Reply

WhisperScout Feb. 18 at 8:02 AM

$MOLN Molecular or unknown micro-cap with minimal public information and likely speculative.

0 · Reply

briefingcom Feb. 2 at 12:44 PM

0 · Reply

BillionerOfKing Jan. 30 at 12:55 PM

$MOLN Current Stock Price: $4.15

0 · Reply

DARKP00L Jan. 27 at 1:17 PM

$MOLN

0 · Reply

DARKP00L Jan. 27 at 11:18 AM

$MOLN 06:16 on Jan. 27 2026 HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13 #tradeideas

0 · Reply

Milos89 Jan. 25 at 2:13 AM

$MOLN

0 · Reply

briefingcom Jan. 12 at 1:11 PM

$MOLN: Molecular Partners (+3.8%) highlights clinical development progress and anticipated milestones at 44th Annual J.P. Morgan Healthcare Conference

0 · Reply

FiscalCycleNavigator Dec. 27 at 8:26 AM

0 · Reply

SuperGreenToday Dec. 22 at 5:20 PM

$MOLN

0 · Reply

JarvisFlow Dec. 8 at 4:10 PM

JP Morgan has adjusted their stance on Molecular Partners ( $MOLN ), setting the rating to Neutral with a target price of 4 → 3.75.

0 · Reply

AlertsAndNews Dec. 7 at 11:00 PM

$MOLN Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting "Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533"

0 · Reply

bilocelhi Nov. 12 at 6:40 PM

$MYNZ 👀 $MOLN

1 · Reply

bilocelhi Nov. 12 at 3:45 PM

$MOLN on watch

0 · Reply

topstockalerts Nov. 3 at 3:48 PM

Top Gainers PT2 $MOLN $NUAI $LGCL $FLUX.X $RNTX

0 · Reply

NVDAMillionaire Oct. 27 at 6:25 PM

$MOLN Great piece that accurately captures MOLN's current position. So if you want to refresh your understanding of MOLN or learn about MOLN for the first time, this is essential reading. https://beyondspx.com/quote/MOLN/analysis/molecular-partners-darpin-innovation-powers-oncology-pipeline-nasdaq-moln

0 · Reply

RadioIsotope25 Sep. 19 at 8:14 PM

$RADX Molecular Partners has almost triple valuation of Radiopharm Theranostics with less of a pipeline significantly $MOLN

0 · Reply

JarvisFlow Sep. 3 at 3:18 PM

JP Morgan updates rating for Molecular Partners ( $MOLN ) to Neutral, target set at 4.5 → 4.

0 · Reply

stockanalysis_ Aug. 25 at 10:32 PM

After Hours Losers: $EPIX $ENGN $CAPS $WAI $MOLN https://stockanalysis.com/markets/afterhours/?ref=saveontrading

0 · Reply

cinnamoncoffee Aug. 25 at 8:13 PM

$MOLN give me 5-7$

0 · Reply

S2K_TP Aug. 23 at 10:43 PM

🚨 Major Monday earnings releases after bell: $SMTC after bell $HEI after bell $FSCO after bell $MOLN after bell $SNT after bell

1 · Reply

Market Cap	201.88M
Revenue (ttm)	5.65M
Net Income (ttm)	-61.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,086.55%
Debt to Equity Ratio	0.00

Volume	137
Avg Vol	4,799
Day's Range	N/A - N/A
Shares Out	40.38M
Stochastic %K	82%
Beta	1.07
Analysts	Strong Sell
Price Target	$10.62